Developer docs
API playgroundTry for free, no card

Search company profiles

Impilo

Full company profile

uuid00025ic

Namestring
Impilo
Legal namestring
Impilo AB
Websiteurl
impilo.se
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Impilo is a Nordic healthcare-focused private equity firm founded in 2016 in Stockholm, Sweden, by former Altor executives Fredrik Strömholm and Jesper Eliasson. The firm invests in pharmaceutical, medical technology, healthcare services, and adjacent health-related companies, primarily in the Nordic region but with growing European and global exposure through its portfolio. Impilo manages approximately EUR 1 billion in capital from leading Nordic and international investors, including pension funds, sovereign wealth funds, insurance companies, family offices, and development finance institutions. The firm operates offices in Stockholm and Copenhagen and maintains a team of 30+ investment professionals spanning Partners, Investment Directors, Investment Managers, CFO, COO, CHRO, and support functions.

The firm's portfolio comprises 20+ healthcare companies spanning specialty pharma (Immedica, Avia Pharma), medical technology (Qufora, Oticon Medical, Stille, Decon, Lowenco), healthcare services (Humana, VaccinDirekt, tandlægen.dk), contract research (Scantox, Pelago Bioscience), health-related insurance (Euro Accident), and adjacent segments. Documented portfolio outcomes include Immedica scaling to EUR 100 million in revenue with 50%+ annual growth under Impilo ownership (since entry May 2018) and Humana reaching 11,300 employees as the market leader in Swedish individual and family care services. Impilo's investment model combines majority or controlling equity stakes with active ownership, board representation, and operational support through full investment cycles from entry to exit.

Impilo closed its first Euro-denominated closed-end fund (Fund II) at the EUR 700 million hard cap in 2025, raising the full amount in just seven months. Fund II's first deployment was the acquisition of Oticon Medical from Demant A/S in a carve-out transaction valued at up to DKK 600 million. In 2024, Impilo formed a strategic partnership with KKR in Immedica Pharma, with KKR acquiring the company and Impilo reinvesting to become equal co-owner alongside KKR's $4.0 billion Health Care Strategic Growth Fund II. Revenue derives from traditional private equity economics — management fees on committed and invested capital plus carried interest from portfolio exits and value creation.

Short descriptiontext

Impilo is a Nordic healthcare-focused private equity firm founded in 2016, managing approximately EUR 1 billion across a diversified portfolio of 20+ pharma, medtech, healthcare services, and CRO companies across the Nordics and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare private equity, Nordic healthcare investment, pharmaceutical investments, medtech buyouts, healthcare portfolio
NAICS code2 codes
  • All Other Financial Investment Activities52399
  • Miscellaneous Financial Investment Activities523999
Product category
Healthcare Private Equity
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management
TypeLicensing Royalties
Description

Impilo generates returns through management of healthcare-focused private equity funds, including management fees and carried interest from portfolio company exits and value creation.

impilo.se
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Impilo is a Nordic healthcare-focused private equity investment firm that acquires controlling or significant stakes in healthcare companies across pharmaceuticals, medical technology, healthcare services, and related sectors. The firm manages approximately EUR 1 billion in capital from Nordic and international institutional investors and provides active ownership through strategic guidance, operational expertise, and capital support to drive growth and value creation in its portfolio of 20+ healthcare companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Fund II raised to EUR 700 million hard cap in 7 months
+1 more record
Product overview1 text field

Impilo is a Nordic healthcare-focused private investment company that does not offer a unified product platform. Instead, it operates as an investment firm managing a diversified portfolio of healthcare companies across multiple sectors including pharmaceuticals (Immedica), healthcare services (Humana), insurance (Euro Accident), medical technology (Qufora, Oticon Medical, Decon), dental care (tandlægen.dk), clinical research services (Scantox, Pelago Bioscience), vaccination services (VaccinDirekt), and surgical instruments (Stille, Avia Pharma). The portfolio companies operate as independent entities with their own products, services, and technological offerings. Each portfolio company represents a distinct brand and product line within the healthcare ecosystem.

Product and service14 records
1Impilo Fund II
CategoryPrivate Equity Fund
Description

Impilo's first Euro-denominated closed-end private equity fund focused on healthcare investments in the Nordic region. The fund is raised from Nordic and international institutional investors and invests in healthcare companies across pharmaceuticals, medical technology, healthcare services, and related sectors.

2Immedica
CategoryPortfolio Company - Specialty Pharmaceuticals
Description

A leading European specialty pharma commercialisation and distribution platform focused on orphan and highly niched indications with high unmet medical needs. Serves patients in more than 50 countries with capabilities in marketing, sales, compliance, pharmacovigilance, quality assurance, regulatory affairs, and medical affairs.

3Humana
CategoryPortfolio Company - Healthcare Services
Description

A leading Nordic care group offering individual and family care services, personal assistance, and elderly care. Market leader in Sweden for individual and family care and personal assistance, second largest in Norway and Finland. Listed on Nasdaq Stockholm with 11,300 employees.

4Euro Accident
CategoryPortfolio Company - Health Insurance
Description

The leading Scandinavian specialist in health-related insurance, active within long-term disability, private health, and group insurance with presence in Denmark and Norway. Employs 534 FTEs.

5Scantox
CategoryPortfolio Company - Contract Research
Description

A leading European GLP-accredited contract research organisation (CRO) specialising in preclinical services that supports global pharmaceutical and biotech companies in their drug development process. Employs 379 FTEs.

6tandlægen.dk
CategoryPortfolio Company - Dental Care
Description

The leading Danish dental care chain comprising 43 clinics across all regions in Denmark, employing over 800 professionals and serving more than 200,000 patients per year. 671 employees.

7Lowenco
CategoryPortfolio Company - Biopharma Equipment
Description

Develops, manufactures, markets, and installs large-scale modular ultra-low temperature (ULT) storage solutions for commercial biopharma, primarily targeting the drug substance market.

8Pelago Bioscience
CategoryPortfolio Company - Contract Research
Description

A drug discovery focused CRO with service offering centred around its patented Cellular Thermal Shift Assay (CETSA) technology for target engagement assessment in whole-cell physiological conditions.

9VaccinDirekt
CategoryPortfolio Company - Retail Vaccination
Description

The largest Nordic retail vaccination provider with network of 46 walk-in clinics and mobile clinics in Sweden, plus operations in Finland. Serves over 1.4 million customers.

10Decon
CategoryPortfolio Company - Medical Technology
Description

A European developer and manufacturer of high-quality electrical power add-on solutions for manual wheelchairs, with direct sales in five European countries and distributor network across more than 25 countries.

11Avia Pharma
CategoryPortfolio Company - Pharmaceuticals
Description

A leading Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany, distributing medically positioned products within dermatology, allergy, women's health, urology and everyday health.

12Stille
CategoryPortfolio Company - Surgical Instruments
Description

A well-established pioneer in the development and manufacturing of premium surgical instruments and advanced surgical tables, with activities in 70+ markets through a broad network of distributors.

13Qufora
CategoryPortfolio Company - Medical Technology
Description

A Danish medical technology product company and innovative market leader within transanal irrigation (TAI) products for patients suffering from bowel dysfunction. Also offers collecting devices. 107 FTEs.

14Oticon Medical
CategoryPortfolio Company - Hearing Healthcare
Description

A global hearing healthcare company specialising in bone-anchored hearing solutions (BAHS), addressing conductive hearing loss. Known for its newly launched Sentio, the smallest and most versatile transcutaneous implant. Operates in more than 25 countries with approximately 30% global market share. 280 employees.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Nordic specialist private equity/growth firm with strong healthcare and technology-enabled care exposure. Overlaps with Impilo on Nordic mid-market healthcare, particularly growth-stage and tech-enabled services.

TypeRegional player
Description

Nordic private equity firm focused on mid-market healthcare, consumer, and services. Comparable in size and geographic focus, and competes for Nordic healthcare buyouts.

TypeRegional player
Description

Swedish mid-market private equity firm with healthcare and business services exposure. Smaller than Impilo but competes for similar Nordic mid-market healthcare opportunities, particularly in Sweden.

TypeBroad incumbent
Description

Swedish-headquartered global private equity firm with a dedicated healthcare team. Competes for Nordic healthcare assets and large LPs, but at materially larger fund size and broader geographic mandate.

TypeBroad incumbent
Description

European private equity firm with deep Nordic roots (formerly IK Investment Partners). Competes for Nordic mid-market healthcare and services assets with similar fund-size profile to Impilo.

TypeDirect peer
Description

Nordic private equity firm with a thematic focus including healthcare, directly comparable to Impilo in geography, fund size, and pure-play sector mandate. Competes for the same Nordic healthcare assets and LPs.

TypeDirect peer
Description

Nordic private equity firm co-founded by Impilo's founders (Strömholm, Eliasson) before they started Impilo. Comparable in geography, fund size, and multi-sector healthcare/services exposure; competes for talent and deals in the Nordics.

TypeBroad incumbent
Description

Large Nordic private equity firm with a long-standing healthcare vertical. Overlaps with Impilo on healthcare buyouts in the Nordics but operates at significantly larger fund size and broader sub-sector mandate.

TypeBroad incumbent
Description

European private equity firm with a healthcare team and Nordic exposure through portfolio companies. Competes for larger Nordic/European healthcare buyouts and serves similar institutional LPs.

TypeBroad incumbent
Description

Global private equity firm with a dedicated healthcare growth strategy and co-owner of Impilo's Immedica. Competes for larger European healthcare platforms and serves as both a peer and capital partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries16 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Impilo

Healthcare Private Equityimpilo.se

Impilo is a Nordic healthcare-focused private equity firm founded in 2016, managing approximately EUR 1 billion across a diversified portfolio of 20+ pharma, medtech, healthcare services, and CRO companies across the Nordics and Europe.

What Impilo does

Impilo is a Nordic healthcare-focused private equity firm founded in 2016 in Stockholm, Sweden, by former Altor executives Fredrik Strömholm and Jesper Eliasson. The firm invests in pharmaceutical, medical technology, healthcare services, and adjacent health-related companies, primarily in the Nordic region but with growing European and global exposure through its portfolio. Impilo manages approximately EUR 1 billion in capital from leading Nordic and international investors, including pension funds, sovereign wealth funds, insurance companies, family offices, and development finance institutions. The firm operates offices in Stockholm and Copenhagen and maintains a team of 30+ investment professionals spanning Partners, Investment Directors, Investment Managers, CFO, COO, CHRO, and support functions.

The firm's portfolio comprises 20+ healthcare companies spanning specialty pharma (Immedica, Avia Pharma), medical technology (Qufora, Oticon Medical, Stille, Decon, Lowenco), healthcare services (Humana, VaccinDirekt, tandlægen.dk), contract research (Scantox, Pelago Bioscience), health-related insurance (Euro Accident), and adjacent segments. Documented portfolio outcomes include Immedica scaling to EUR 100 million in revenue with 50%+ annual growth under Impilo ownership (since entry May 2018) and Humana reaching 11,300 employees as the market leader in Swedish individual and family care services. Impilo's investment model combines majority or controlling equity stakes with active ownership, board representation, and operational support through full investment cycles from entry to exit.

Impilo closed its first Euro-denominated closed-end fund (Fund II) at the EUR 700 million hard cap in 2025, raising the full amount in just seven months. Fund II's first deployment was the acquisition of Oticon Medical from Demant A/S in a carve-out transaction valued at up to DKK 600 million. In 2024, Impilo formed a strategic partnership with KKR in Immedica Pharma, with KKR acquiring the company and Impilo reinvesting to become equal co-owner alongside KKR's $4.0 billion Health Care Strategic Growth Fund II. Revenue derives from traditional private equity economics — management fees on committed and invested capital plus carried interest from portfolio exits and value creation.

Impilo firmographics

Firmographics
Name
Impilo
Legal name
Impilo AB
Website
https://impilo.se
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Impilo is a Nordic healthcare-focused private equity firm founded in 2016, managing approximately EUR 1 billion across a diversified portfolio of 20+ pharma, medtech, healthcare services, and CRO companies across the Nordics and Europe.
Ownership category
akta.pro rank

Where Impilo is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Impilo business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Investment Management: Impilo generates returns through management of healthcare-focused private equity funds, including management fees and carried interest from portfolio company exits and value creation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Impilo product offering

Product offering

Core offering

Impilo is a Nordic healthcare-focused private equity investment firm that acquires controlling or significant stakes in healthcare companies across pharmaceuticals, medical technology, healthcare services, and related sectors. The firm manages approximately EUR 1 billion in capital from Nordic and international institutional investors and provides active ownership through strategic guidance, operational expertise, and capital support to drive growth and value creation in its portfolio of 20+ healthcare companies.

Product overview

Impilo is a Nordic healthcare-focused private investment company that does not offer a unified product platform. Instead, it operates as an investment firm managing a diversified portfolio of healthcare companies across multiple sectors including pharmaceuticals (Immedica), healthcare services (Humana), insurance (Euro Accident), medical technology (Qufora, Oticon Medical, Decon), dental care (tandlægen.dk), clinical research services (Scantox, Pelago Bioscience), vaccination services (VaccinDirekt), and surgical instruments (Stille, Avia Pharma). The portfolio companies operate as independent entities with their own products, services, and technological offerings. Each portfolio company represents a distinct brand and product line within the healthcare ecosystem.

Differentiator

Problem solved

Functional benefit

Products and services

  • Impilo Fund II Impilo's first Euro-denominated closed-end private equity fund focused on healthcare investments in the Nordic region. The fund is raised from Nordic and international institutional investors and invests in healthcare companies across pharmaceuticals, medical technology, healthcare services, and related sectors.
  • Immedica A leading European specialty pharma commercialisation and distribution platform focused on orphan and highly niched indications with high unmet medical needs. Serves patients in more than 50 countries with capabilities in marketing, sales, compliance, pharmacovigilance, quality assurance, regulatory affairs, and medical affairs.
  • Humana A leading Nordic care group offering individual and family care services, personal assistance, and elderly care. Market leader in Sweden for individual and family care and personal assistance, second largest in Norway and Finland. Listed on Nasdaq Stockholm with 11,300 employees.
  • Euro Accident The leading Scandinavian specialist in health-related insurance, active within long-term disability, private health, and group insurance with presence in Denmark and Norway. Employs 534 FTEs.
  • Scantox A leading European GLP-accredited contract research organisation (CRO) specialising in preclinical services that supports global pharmaceutical and biotech companies in their drug development process. Employs 379 FTEs.
  • tandlægen.dk The leading Danish dental care chain comprising 43 clinics across all regions in Denmark, employing over 800 professionals and serving more than 200,000 patients per year. 671 employees.
  • Lowenco Develops, manufactures, markets, and installs large-scale modular ultra-low temperature (ULT) storage solutions for commercial biopharma, primarily targeting the drug substance market.
  • Pelago Bioscience A drug discovery focused CRO with service offering centred around its patented Cellular Thermal Shift Assay (CETSA) technology for target engagement assessment in whole-cell physiological conditions.
  • VaccinDirekt The largest Nordic retail vaccination provider with network of 46 walk-in clinics and mobile clinics in Sweden, plus operations in Finland. Serves over 1.4 million customers.
  • Decon A European developer and manufacturer of high-quality electrical power add-on solutions for manual wheelchairs, with direct sales in five European countries and distributor network across more than 25 countries.
  • Avia Pharma A leading Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany, distributing medically positioned products within dermatology, allergy, women's health, urology and everyday health.
  • Stille A well-established pioneer in the development and manufacturing of premium surgical instruments and advanced surgical tables, with activities in 70+ markets through a broad network of distributors.
  • Qufora A Danish medical technology product company and innovative market leader within transanal irrigation (TAI) products for patients suffering from bowel dysfunction. Also offers collecting devices. 107 FTEs.
  • Oticon Medical A global hearing healthcare company specialising in bone-anchored hearing solutions (BAHS), addressing conductive hearing loss. Known for its newly launched Sentio, the smallest and most versatile transcutaneous implant. Operates in more than 25 countries with approximately 30% global market share. 280 employees.

Quantifiable outcome

  • Fund II raised to EUR 700 million hard cap in 7 months
  • +1 more outcomes

Companies that use Impilo

Customer profile

Named customers7 records

Segments1 record

Ideal customer profiles2 records

Impilo technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Impilo partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Impilo competitors and assessment

Company assessment

Direct peers

  • Verdane: Nordic specialist private equity/growth firm with strong healthcare and technology-enabled care exposure. Overlaps with Impilo on Nordic mid-market healthcare, particularly growth-stage and tech-enabled services.
  • Summa Equity: Nordic private equity firm with a thematic focus including healthcare, directly comparable to Impilo in geography, fund size, and pure-play sector mandate. Competes for the same Nordic healthcare assets and LPs.
  • Altor Equity Partners: Nordic private equity firm co-founded by Impilo's founders (Strömholm, Eliasson) before they started Impilo. Comparable in geography, fund size, and multi-sector healthcare/services exposure; competes for talent and deals in the Nordics.

Regional players

  • Norvestor: Nordic private equity firm focused on mid-market healthcare, consumer, and services. Comparable in size and geographic focus, and competes for Nordic healthcare buyouts.
  • Litorina: Swedish mid-market private equity firm with healthcare and business services exposure. Smaller than Impilo but competes for similar Nordic mid-market healthcare opportunities, particularly in Sweden.

Broad incumbents

  • EQT: Swedish-headquartered global private equity firm with a dedicated healthcare team. Competes for Nordic healthcare assets and large LPs, but at materially larger fund size and broader geographic mandate.
  • IK Partners: European private equity firm with deep Nordic roots (formerly IK Investment Partners). Competes for Nordic mid-market healthcare and services assets with similar fund-size profile to Impilo.
  • Nordic Capital: Large Nordic private equity firm with a long-standing healthcare vertical. Overlaps with Impilo on healthcare buyouts in the Nordics but operates at significantly larger fund size and broader sub-sector mandate.
  • BC Partners: European private equity firm with a healthcare team and Nordic exposure through portfolio companies. Competes for larger Nordic/European healthcare buyouts and serves similar institutional LPs.
  • KKR (Health Care Strategic Growth): Global private equity firm with a dedicated healthcare growth strategy and co-owner of Impilo's Immedica. Competes for larger European healthcare platforms and serves as both a peer and capital partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Impilo social profiles

Digital presence

Impilo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Impilo leadership team

Management profile

Number of profiles

Profiles10 records

Impilo subsidiaries and ownership

Company hierarchy

Subsidiaries16 records

Impilo funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Impilo M&A and investment

M&A and investment

M&A6 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Impilo

What does Impilo do?

Impilo is a Nordic healthcare-focused private equity investment firm that acquires controlling or significant stakes in healthcare companies across pharmaceuticals, medical technology, healthcare services, and related sectors. The firm manages approximately EUR 1 billion in capital from Nordic and international institutional investors and provides active ownership through strategic guidance, operational expertise, and capital support to drive growth and value creation in its portfolio of 20+ healthcare companies.

Is Impilo a public or private company?

Impilo is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Impilo founded?

Impilo was founded in 2016. It employs 11 to 50 people.

Where is Impilo based?

Impilo is headquartered in Stockholm, Sweden, in the Europe region.

How does Impilo make money?

One revenue line is on record: investment Management.

Who are Impilo's main competitors?

Direct peers on record are Verdane, Summa Equity and Altor Equity Partners. Regional players are Norvestor and Litorina. Broad incumbents are EQT, IK Partners, Nordic Capital, BC Partners and KKR (Health Care Strategic Growth).

Does Impilo have an API?

No public API is recorded for Impilo.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestorsinhealthcareDenmark: Impilo takes ownership of XO CareImpilo, a Nordic investment company, acquired Denmark-based dental unit manufacturer XO Care. The deal followed CEO Kim Sørensen's decision to retire, after which he will remain...Dagens industriStorägaren om budet: ”En bra lösning”Ambea has made a bid to acquire Humana, and Humana's largest shareholder Impilo has expressed support for the deal. Impilo partner Fredrik Strömholm called it "a good solution" and noted the group will be stronger after the transaction. If the bid is approved, Impilo will become a major shareholder in Ambea instead.PitchBookHealthcare funds are winning the fight for investor dollarsHealthcare buyout funds raised 4.2% less capital in 2025 than generalist funds, but still outperformed the broader PE market. 75.8% of healthcare funds hit their targets, versus 72.6% for generalist funds. Investors are increasingly backing specialist managers and mega-funds.ImpiloImpilo Acquires Scantox A/S, a Leading Danish Pre-Clinical Contract ResearchImpilo acquired Scantox A/S, a Danish pre-clinical CRO, with its management team. The company, formerly Charles River Copenhagen, will continue as an independent entity. Impilo aims to expand Scantox's geographic footprint and service offerings.news.cision.comImpilo acquires Oticon Medical from DemantImpilo, a Nordic investment company focused on healthcare, has agreed to acquire Oticon Medical, a global leader in bone-anchored hearing solutions, from Demant A/S. The transaction represents Impilo's first investment from its recently raised Fund II and will transition Oticon Medical to a standalone company, with Demant providing transitional support including product supply and administrative services. The deal is subject to customary closing conditions and regulatory approvals, with closing expected by the end of Q1 2026.NasdaqDemant To Sell Oticon Medical To Impilo For Up To DKK 600 MlnDemant A/S has agreed to sell its Oticon Medical business segment to Nordic investment company Impilo for up to 600 million Danish Kroner, with 325 million DKK paid in cash at closing and the remainder in milestone payments tied to performance targets. The transaction, expected to close by Q1 2026, completes the divestiture of Demant's Hearing Implants business segment and includes transitional support services from Demant to help Oticon Medical establish standalone operations. Proceeds from the sale will be added to Demant's cash reserves, and the company's shares rose 0.42% following the announcement.ImpiloImpilo acquires Oticon Medical from DemantImpilo has agreed to acquire Oticon Medical AB, a global leader in bone-anchored hearing solutions, from Demant A/S. The transaction, the first investment from Impilo's new flagship fund, will support Oticon Medical's transition to a standalone company while driving growth and advancing next-generation hearing technologies.Investing.comDemant sells BAHS business to Impilo for up to DKK600m By Investing.comDemant has agreed to sell its BAHS business to Nordic investor Impilo for up to DKK600 million, with DKK325 million paid at closing anticipated by early 2026. The transaction results in an estimated loss of approximately DKK200 million from discontinued operations, allowing Demant to concentrate on its core hearing aids and diagnostics segments. The move comes ahead of the EUHA industry event where new hearing aid products are expected to be announced, potentially impacting Demant's market momentum.Morgan StanleyImpilo Closes Single Asset ContinuationImpilo and KKR announced on September 20, 2024 the completion of their joint acquisition of Stockholm-based Immedica Pharma, a rare disease and specialty care commercialization company. Immedica has generated EUR 100m in revenue with over 50% annual growth, employing more than 120 people across Europe, the Middle East and the U.S. Morgan Stanley Private Equity Secondaries and Hayfin were lead investors.ImpiloKKR and Impilo announce strategic partnership together with management in rare disease platform Immedica PharmaKKR has agreed to acquire Immedica Pharma, a Stockholm-based rare disease pharmaceutical company, with existing owner Impilo reinvesting to become an equal partner in the transaction. The investment will support Immedica's growth strategies, including the launch of its ultra-orphan drug Loargys and potential expansion into the U.S. market.